Global Infectious Disease Treatment Market

Infectious Disease Treatment Comprehensive Study by Application (Humans, Animals), Treatment (Antibiotics, Antivirals, Antifungals, Anti-parasitics), Cause (Viruses, Bacteria, Fungi, Parasites), Diagnosis (Laboratory tests, Imaging scans, Biopsies, Other), Symptoms (Fever, Chills, Congestion, Fatigue, Muscle aches and headache) Players and Region - Global Market Outlook to 2030

Infectious Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Infectious Disease Treatment
Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi or parasites. Many organisms live in bodies. They are normally harmless or even helpful. However, under certain conditions, some organisms may cause disease. Some infectious diseases can be passed from person to person. Insects or other animals transmit some. In addition, may get others by consuming contaminated food or water or being exposed to organisms in the environment. Signs and symptoms vary depending on the organism causing the infection, but often include fever and fatigue. Mild infections may respond to rest and home remedies, while some life-threatening infections may need hospitalization. Treatment depends on which microorganism causes the infection. If bacteria cause disease, treatment with antibiotics usually kills the bacteria and ends the infection. Viral infections are usually treated with supportive therapies, like rest and increased fluid intake

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.0%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Infectious Disease Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer, Inc. (United States), ABBVIE (United States), Amgen (United States), Roche (Switzerland), Merck & Co., Inc. (aka MSD) (United States), Genentech (United States), emocha Mobile Health (United States), Inovio Pharmaceuticals (United States), Sanofi (France) and GlaxoSmithKline (GSK) (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Soligenix (United States), Heat Biologics (United States) and Regeneron (United States).

Segmentation Overview
AMA Research has segmented the market of Global Infectious Disease Treatment market by , Application (Humans and Animals) and Region.



On the basis of geography, the market of Infectious Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Antibiotics will boost the Infectious Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cause, the sub-segment i.e. Viruses will boost the Infectious Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Laboratory tests will boost the Infectious Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Fever will boost the Infectious Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Investments in Healthcare R&D

Market Growth Drivers:
Rising prevalence of Infectious Disease and Rising geriatric population

Challenges:
Limited expertise and high cost of treatment

Restraints:
Lack of awareness about the disease and Technical complexities related to diagnostic test

Opportunities:
High governmental healthcare expenditure and Surging insurance penetration

Market Leaders and their expansionary development strategies
In July 2023, Gilead Sciences, Inc. announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness.
In July 2023, CDER approved 55 novel drugs, as detailed in our annual New Drug Therapy Approvals report. The active ingredient(s) in a novel drug have not been previously FDA-approved. We also took other important actions, such as expanding the indications or patient populations of some previously approved therapies. In addition, we approved new dosage forms or drug formulations and made some prescription drugs available over-the-counter.


Key Target Audience
Infectious Disease Treatment Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Humans
  • Animals
By Treatment
  • Antibiotics
  • Antivirals
  • Antifungals
  • Anti-parasitics

By Cause
  • Viruses
  • Bacteria
  • Fungi
  • Parasites

By Diagnosis
  • Laboratory tests
  • Imaging scans
  • Biopsies
  • Other

By Symptoms
  • Fever
  • Chills
  • Congestion
  • Fatigue
  • Muscle aches and headache

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of Infectious Disease
      • 3.2.2. Rising geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Limited expertise and high cost of treatment
    • 3.4. Market Trends
      • 3.4.1. High Investments in Healthcare R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Infectious Disease Treatment, by Application, Treatment, Cause, Diagnosis, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Infectious Disease Treatment (Value)
      • 5.2.1. Global Infectious Disease Treatment by: Application (Value)
        • 5.2.1.1. Humans
        • 5.2.1.2. Animals
      • 5.2.2. Global Infectious Disease Treatment by: Treatment (Value)
        • 5.2.2.1. Antibiotics
        • 5.2.2.2. Antivirals
        • 5.2.2.3. Antifungals
        • 5.2.2.4. Anti-parasitics
      • 5.2.3. Global Infectious Disease Treatment by: Cause (Value)
        • 5.2.3.1. Viruses
        • 5.2.3.2. Bacteria
        • 5.2.3.3. Fungi
        • 5.2.3.4. Parasites
      • 5.2.4. Global Infectious Disease Treatment by: Diagnosis (Value)
        • 5.2.4.1. Laboratory tests
        • 5.2.4.2. Imaging scans
        • 5.2.4.3. Biopsies
        • 5.2.4.4. Other
      • 5.2.5. Global Infectious Disease Treatment by: Symptoms (Value)
        • 5.2.5.1. Fever
        • 5.2.5.2. Chills
        • 5.2.5.3. Congestion
        • 5.2.5.4. Fatigue
        • 5.2.5.5. Muscle aches and headache
      • 5.2.6. Global Infectious Disease Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Infectious Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ABBVIE (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (aka MSD) (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Emocha Mobile Health (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Inovio Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (GSK) (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Infectious Disease Treatment Sale, by Application, Treatment, Cause, Diagnosis, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Infectious Disease Treatment (Value)
      • 7.2.1. Global Infectious Disease Treatment by: Application (Value)
        • 7.2.1.1. Humans
        • 7.2.1.2. Animals
      • 7.2.2. Global Infectious Disease Treatment by: Treatment (Value)
        • 7.2.2.1. Antibiotics
        • 7.2.2.2. Antivirals
        • 7.2.2.3. Antifungals
        • 7.2.2.4. Anti-parasitics
      • 7.2.3. Global Infectious Disease Treatment by: Cause (Value)
        • 7.2.3.1. Viruses
        • 7.2.3.2. Bacteria
        • 7.2.3.3. Fungi
        • 7.2.3.4. Parasites
      • 7.2.4. Global Infectious Disease Treatment by: Diagnosis (Value)
        • 7.2.4.1. Laboratory tests
        • 7.2.4.2. Imaging scans
        • 7.2.4.3. Biopsies
        • 7.2.4.4. Other
      • 7.2.5. Global Infectious Disease Treatment by: Symptoms (Value)
        • 7.2.5.1. Fever
        • 7.2.5.2. Chills
        • 7.2.5.3. Congestion
        • 7.2.5.4. Fatigue
        • 7.2.5.5. Muscle aches and headache
      • 7.2.6. Global Infectious Disease Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Infectious Disease Treatment: by Application(USD Million)
  • Table 2. Infectious Disease Treatment Humans , by Region USD Million (2018-2023)
  • Table 3. Infectious Disease Treatment Animals , by Region USD Million (2018-2023)
  • Table 4. Infectious Disease Treatment: by Treatment(USD Million)
  • Table 5. Infectious Disease Treatment Antibiotics , by Region USD Million (2018-2023)
  • Table 6. Infectious Disease Treatment Antivirals , by Region USD Million (2018-2023)
  • Table 7. Infectious Disease Treatment Antifungals , by Region USD Million (2018-2023)
  • Table 8. Infectious Disease Treatment Anti-parasitics , by Region USD Million (2018-2023)
  • Table 9. Infectious Disease Treatment: by Cause(USD Million)
  • Table 10. Infectious Disease Treatment Viruses , by Region USD Million (2018-2023)
  • Table 11. Infectious Disease Treatment Bacteria , by Region USD Million (2018-2023)
  • Table 12. Infectious Disease Treatment Fungi , by Region USD Million (2018-2023)
  • Table 13. Infectious Disease Treatment Parasites , by Region USD Million (2018-2023)
  • Table 14. Infectious Disease Treatment: by Diagnosis(USD Million)
  • Table 15. Infectious Disease Treatment Laboratory tests , by Region USD Million (2018-2023)
  • Table 16. Infectious Disease Treatment Imaging scans , by Region USD Million (2018-2023)
  • Table 17. Infectious Disease Treatment Biopsies , by Region USD Million (2018-2023)
  • Table 18. Infectious Disease Treatment Other , by Region USD Million (2018-2023)
  • Table 19. Infectious Disease Treatment: by Symptoms(USD Million)
  • Table 20. Infectious Disease Treatment Fever , by Region USD Million (2018-2023)
  • Table 21. Infectious Disease Treatment Chills , by Region USD Million (2018-2023)
  • Table 22. Infectious Disease Treatment Congestion , by Region USD Million (2018-2023)
  • Table 23. Infectious Disease Treatment Fatigue , by Region USD Million (2018-2023)
  • Table 24. Infectious Disease Treatment Muscle aches and headache , by Region USD Million (2018-2023)
  • Table 25. South America Infectious Disease Treatment, by Country USD Million (2018-2023)
  • Table 26. South America Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 27. South America Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 28. South America Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 29. South America Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 30. South America Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 31. Brazil Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 32. Brazil Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 33. Brazil Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 34. Brazil Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 35. Brazil Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 36. Argentina Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 37. Argentina Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 38. Argentina Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 39. Argentina Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 40. Argentina Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 41. Rest of South America Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 42. Rest of South America Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 43. Rest of South America Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 44. Rest of South America Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 45. Rest of South America Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 46. Asia Pacific Infectious Disease Treatment, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 49. Asia Pacific Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 50. Asia Pacific Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 51. Asia Pacific Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 52. China Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 53. China Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 54. China Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 55. China Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 56. China Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 57. Japan Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 58. Japan Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 59. Japan Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 60. Japan Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 61. Japan Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 62. India Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 63. India Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 64. India Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 65. India Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 66. India Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 67. South Korea Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 68. South Korea Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 69. South Korea Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 70. South Korea Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 71. South Korea Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 72. Taiwan Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 73. Taiwan Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 74. Taiwan Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 75. Taiwan Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 76. Taiwan Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 77. Australia Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 78. Australia Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 79. Australia Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 80. Australia Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 81. Australia Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 87. Europe Infectious Disease Treatment, by Country USD Million (2018-2023)
  • Table 88. Europe Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 89. Europe Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 90. Europe Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 91. Europe Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 92. Europe Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 93. Germany Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 94. Germany Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 95. Germany Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 96. Germany Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 97. Germany Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 98. France Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 99. France Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 100. France Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 101. France Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 102. France Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 103. Italy Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 104. Italy Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 105. Italy Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 106. Italy Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 107. Italy Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 108. United Kingdom Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 109. United Kingdom Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 110. United Kingdom Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 111. United Kingdom Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 112. United Kingdom Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 113. Netherlands Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 114. Netherlands Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 115. Netherlands Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 116. Netherlands Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 117. Netherlands Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 118. Rest of Europe Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 119. Rest of Europe Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 120. Rest of Europe Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 121. Rest of Europe Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 122. Rest of Europe Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 123. MEA Infectious Disease Treatment, by Country USD Million (2018-2023)
  • Table 124. MEA Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 125. MEA Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 126. MEA Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 127. MEA Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 128. MEA Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 129. Middle East Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 130. Middle East Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 131. Middle East Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 132. Middle East Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 133. Middle East Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 134. Africa Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 135. Africa Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 136. Africa Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 137. Africa Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 138. Africa Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 139. North America Infectious Disease Treatment, by Country USD Million (2018-2023)
  • Table 140. North America Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 141. North America Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 142. North America Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 143. North America Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 144. North America Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 145. United States Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 146. United States Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 147. United States Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 148. United States Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 149. United States Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 150. Canada Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 151. Canada Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 152. Canada Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 153. Canada Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 154. Canada Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 155. Mexico Infectious Disease Treatment, by Application USD Million (2018-2023)
  • Table 156. Mexico Infectious Disease Treatment, by Treatment USD Million (2018-2023)
  • Table 157. Mexico Infectious Disease Treatment, by Cause USD Million (2018-2023)
  • Table 158. Mexico Infectious Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 159. Mexico Infectious Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Infectious Disease Treatment: by Application(USD Million)
  • Table 171. Infectious Disease Treatment Humans , by Region USD Million (2025-2030)
  • Table 172. Infectious Disease Treatment Animals , by Region USD Million (2025-2030)
  • Table 173. Infectious Disease Treatment: by Treatment(USD Million)
  • Table 174. Infectious Disease Treatment Antibiotics , by Region USD Million (2025-2030)
  • Table 175. Infectious Disease Treatment Antivirals , by Region USD Million (2025-2030)
  • Table 176. Infectious Disease Treatment Antifungals , by Region USD Million (2025-2030)
  • Table 177. Infectious Disease Treatment Anti-parasitics , by Region USD Million (2025-2030)
  • Table 178. Infectious Disease Treatment: by Cause(USD Million)
  • Table 179. Infectious Disease Treatment Viruses , by Region USD Million (2025-2030)
  • Table 180. Infectious Disease Treatment Bacteria , by Region USD Million (2025-2030)
  • Table 181. Infectious Disease Treatment Fungi , by Region USD Million (2025-2030)
  • Table 182. Infectious Disease Treatment Parasites , by Region USD Million (2025-2030)
  • Table 183. Infectious Disease Treatment: by Diagnosis(USD Million)
  • Table 184. Infectious Disease Treatment Laboratory tests , by Region USD Million (2025-2030)
  • Table 185. Infectious Disease Treatment Imaging scans , by Region USD Million (2025-2030)
  • Table 186. Infectious Disease Treatment Biopsies , by Region USD Million (2025-2030)
  • Table 187. Infectious Disease Treatment Other , by Region USD Million (2025-2030)
  • Table 188. Infectious Disease Treatment: by Symptoms(USD Million)
  • Table 189. Infectious Disease Treatment Fever , by Region USD Million (2025-2030)
  • Table 190. Infectious Disease Treatment Chills , by Region USD Million (2025-2030)
  • Table 191. Infectious Disease Treatment Congestion , by Region USD Million (2025-2030)
  • Table 192. Infectious Disease Treatment Fatigue , by Region USD Million (2025-2030)
  • Table 193. Infectious Disease Treatment Muscle aches and headache , by Region USD Million (2025-2030)
  • Table 194. South America Infectious Disease Treatment, by Country USD Million (2025-2030)
  • Table 195. South America Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 196. South America Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 197. South America Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 198. South America Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 199. South America Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 200. Brazil Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 201. Brazil Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 202. Brazil Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 203. Brazil Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 204. Brazil Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 205. Argentina Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 206. Argentina Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 207. Argentina Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 208. Argentina Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 209. Argentina Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 210. Rest of South America Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 211. Rest of South America Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 212. Rest of South America Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 213. Rest of South America Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 214. Rest of South America Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 215. Asia Pacific Infectious Disease Treatment, by Country USD Million (2025-2030)
  • Table 216. Asia Pacific Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 217. Asia Pacific Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 218. Asia Pacific Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 219. Asia Pacific Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 220. Asia Pacific Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 221. China Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 222. China Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 223. China Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 224. China Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 225. China Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 226. Japan Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 227. Japan Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 228. Japan Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 229. Japan Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 230. Japan Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 231. India Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 232. India Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 233. India Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 234. India Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 235. India Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 236. South Korea Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 237. South Korea Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 238. South Korea Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 239. South Korea Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 240. South Korea Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 241. Taiwan Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 242. Taiwan Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 243. Taiwan Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 244. Taiwan Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 245. Taiwan Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 246. Australia Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 247. Australia Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 248. Australia Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 249. Australia Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 250. Australia Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 251. Rest of Asia-Pacific Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 255. Rest of Asia-Pacific Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 256. Europe Infectious Disease Treatment, by Country USD Million (2025-2030)
  • Table 257. Europe Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 258. Europe Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 259. Europe Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 260. Europe Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 261. Europe Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 262. Germany Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 263. Germany Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 264. Germany Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 265. Germany Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 266. Germany Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 267. France Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 268. France Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 269. France Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 270. France Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 271. France Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 272. Italy Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 273. Italy Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 274. Italy Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 275. Italy Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 276. Italy Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 277. United Kingdom Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 278. United Kingdom Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 279. United Kingdom Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 280. United Kingdom Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 281. United Kingdom Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 282. Netherlands Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 283. Netherlands Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 284. Netherlands Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 285. Netherlands Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 286. Netherlands Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 287. Rest of Europe Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 288. Rest of Europe Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 289. Rest of Europe Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 290. Rest of Europe Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 291. Rest of Europe Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 292. MEA Infectious Disease Treatment, by Country USD Million (2025-2030)
  • Table 293. MEA Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 294. MEA Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 295. MEA Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 296. MEA Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 297. MEA Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 298. Middle East Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 299. Middle East Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 300. Middle East Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 301. Middle East Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 302. Middle East Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 303. Africa Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 304. Africa Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 305. Africa Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 306. Africa Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 307. Africa Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 308. North America Infectious Disease Treatment, by Country USD Million (2025-2030)
  • Table 309. North America Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 310. North America Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 311. North America Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 312. North America Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 313. North America Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 314. United States Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 315. United States Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 316. United States Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 317. United States Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 318. United States Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 319. Canada Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 320. Canada Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 321. Canada Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 322. Canada Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 323. Canada Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 324. Mexico Infectious Disease Treatment, by Application USD Million (2025-2030)
  • Table 325. Mexico Infectious Disease Treatment, by Treatment USD Million (2025-2030)
  • Table 326. Mexico Infectious Disease Treatment, by Cause USD Million (2025-2030)
  • Table 327. Mexico Infectious Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 328. Mexico Infectious Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 329. Research Programs/Design for This Report
  • Table 330. Key Data Information from Secondary Sources
  • Table 331. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Infectious Disease Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Infectious Disease Treatment: by Treatment USD Million (2018-2023)
  • Figure 6. Global Infectious Disease Treatment: by Cause USD Million (2018-2023)
  • Figure 7. Global Infectious Disease Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 8. Global Infectious Disease Treatment: by Symptoms USD Million (2018-2023)
  • Figure 9. South America Infectious Disease Treatment Share (%), by Country
  • Figure 10. Asia Pacific Infectious Disease Treatment Share (%), by Country
  • Figure 11. Europe Infectious Disease Treatment Share (%), by Country
  • Figure 12. MEA Infectious Disease Treatment Share (%), by Country
  • Figure 13. North America Infectious Disease Treatment Share (%), by Country
  • Figure 14. Global Infectious Disease Treatment share by Players 2023 (%)
  • Figure 15. Global Infectious Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 16. Global Infectious Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 20. ABBVIE (United States) Revenue, Net Income and Gross profit
  • Figure 21. ABBVIE (United States) Revenue: by Geography 2023
  • Figure 22. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 23. Amgen (United States) Revenue: by Geography 2023
  • Figure 24. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 26. Merck & Co., Inc. (aka MSD) (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co., Inc. (aka MSD) (United States) Revenue: by Geography 2023
  • Figure 28. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 29. Genentech (United States) Revenue: by Geography 2023
  • Figure 30. Emocha Mobile Health (United States) Revenue, Net Income and Gross profit
  • Figure 31. Emocha Mobile Health (United States) Revenue: by Geography 2023
  • Figure 32. Inovio Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Inovio Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2023
  • Figure 36. GlaxoSmithKline (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GlaxoSmithKline (GSK) (United Kingdom) Revenue: by Geography 2023
  • Figure 38. Global Infectious Disease Treatment: by Application USD Million (2025-2030)
  • Figure 39. Global Infectious Disease Treatment: by Treatment USD Million (2025-2030)
  • Figure 40. Global Infectious Disease Treatment: by Cause USD Million (2025-2030)
  • Figure 41. Global Infectious Disease Treatment: by Diagnosis USD Million (2025-2030)
  • Figure 42. Global Infectious Disease Treatment: by Symptoms USD Million (2025-2030)
  • Figure 43. South America Infectious Disease Treatment Share (%), by Country
  • Figure 44. Asia Pacific Infectious Disease Treatment Share (%), by Country
  • Figure 45. Europe Infectious Disease Treatment Share (%), by Country
  • Figure 46. MEA Infectious Disease Treatment Share (%), by Country
  • Figure 47. North America Infectious Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer, Inc. (United States)
  • ABBVIE (United States)
  • Amgen (United States)
  • Roche (Switzerland)
  • Merck & Co., Inc. (aka MSD) (United States)
  • Genentech (United States)
  • emocha Mobile Health (United States)
  • Inovio Pharmaceuticals (United States)
  • Sanofi (France)
  • GlaxoSmithKline (GSK) (United Kingdom)
Additional players considered in the study are as follows:
Soligenix (United States) , Heat Biologics (United States) , Regeneron (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 235 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Infectious Disease Treatment Market Quantitative research analysis
Global Infectious Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer, Inc. (United States), ABBVIE (United States), Amgen (United States), Roche (Switzerland), Merck & Co., Inc. (aka MSD) (United States), Genentech (United States), emocha Mobile Health (United States), Inovio Pharmaceuticals (United States), Sanofi (France) and GlaxoSmithKline (GSK) (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Investments in Healthcare R&D" is seen as one of major influencing trends for Infectious Disease Treatment Market during projected period 2023-2030.
The Infectious Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Infectious Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Xerostomia Treatments Comprehensive Study by Type (OTC, Prescription), Application (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Treatment Type (Artificial Saliva, Salivary Stimulants,...
$ 3650
Anticoagulation Therapy Comprehensive Study by Application (Venous Thromboembolism, Deep Vein Thrombosis, Coronary Artery Disease, Heart Attack), Route of Administration (Oral, Parenteral), Distribut...
$ 3750
Toxoid Vaccines Comprehensive Study by Type (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (DTaP), Diphtheria and Tetanus (DT)), Forms (Quadrivalent, Pentavalent, Hexavalent), End-us...
$ 3450
Ophthalmoplegia Comprehensive Study by Type (External Ophthalmoplegia, Internuclear Ophthalmoplegia), Application (Telemedicine Platforms, Assistive Technology Application, Low Vision Aid Apps), End ...
$ 3500
Brain Tumor Diagnosis and Treatments Comprehensive Study by Type (Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors), Secondary Brain Tumor), Applic...
$ 3750
Tuberculosis Treatment Drugs Comprehensive Study by Type (Active TB, Latent TB), Application (Hospital, Clinic, Durgstore), Drugs (First Line anti-TB Drugs, Second Line anti- TB Drugs) Players and Re...
$ 3500